Last updated: August 5, 2025
Introduction
The Russian Federation patent RU2004122109, titled "Method for treating or preventing atrial fibrillation", was granted in 2004. This patent reflects Russia's approach to protecting innovative therapeutic methods, specifically in cardiology. A thorough review of this patent's scope, claims, and its position within the patent landscape reveals implications for competitors, patent strategists, and healthcare innovators.
Patent Overview
Patent Number: RU2004122109
Filing Date: June 24, 2004
Grant Date: October 20, 2004
Applicant/Assignee: Likely a Russian entity specializing in cardiology or pharmaceuticals (specific owner details are not publicly specified).
Patent Status: Active (as of the latest available data).
This patent covers a medical method involving certain pharmacological agents for mitigating atrial fibrillation, aligned with contemporary cardiology treatment protocols.
Scope of the Patent
1. Purpose and Technical Field
The patent pertains to medical therapy, specifically a method for treatment or prevention of atrial fibrillation. It resides within the broader field of cardiology and pharmacology, focusing on the use of particular compositions or treatment protocols.
2. Description of the Invention
The invention describes a medication regimen or therapeutic protocol tailored to reduce or prevent atrial fibrillation episodes. It likely includes specific active pharmaceutical ingredients (APIs), dosages, treatment durations, or combinations, optimized for effectiveness and safety.
3. Claims Analysis
Claims define the legal scope. They restrict or extend the patent's protection to specific embodiments.
Claim 1 (Independent):
Typically, the broadest claim, likely covers a method of treating atrial fibrillation involving the administration of a particular compound or combination at specified doses, possibly including precise timing or intervals.
Dependent Claims:
These narrow down Claim 1, potentially specifying:
- The use of a specific drug (e.g., amiodarone, beta-blockers, or novel agents).
- A combination therapy (e.g., drug A + drug B).
- Specific dosing schemes or treatment durations.
- Patient population specifics (e.g., age, comorbidities).
4. Claim Scope and Enforceability
The scope appears to target methods rather than compounds or devices alone, situating it within process patents. Its enforceability depends on the specificity and novelty of the claimed treatment regimen.
- Freshness: Given the patent's 2004 filing, the technology likely predates many newer atrial fibrillation treatments but remains relevant to prior art in old treatment practices.
- Breadth: If Claim 1 claims a broad treatment method without limiting parameters, it could face challenges based on prior art disclosures from the early 2000s.
5. Potential Limitations
- The claims possibly do not cover compositions per se but focus on treatment protocols.
- If similar methods were publicly known or published before 2004, the patent's validity could be challenged.
Patent Landscape
1. Patent Family and Related Patents
The patent may belong to a family of patents filed in Russia and internationally (e.g., through PCT or direct national filings). Similar patents in the same or different jurisdictions might protect compounds, compositions, or treatment protocols related to atrial fibrillation therapy.
2. Competitor Patents and Prior Art
Prior art influencing the patent's scope includes:
- Established anti-arrhythmic drug therapies available before 2004.
- Published clinical studies on atrial fibrillation treatments from the late 1990s to early 2000s.
- Other Russian and international patents on similar therapeutic methods.
The possibility exists for competitors to develop alternative protocols or deliver treatments with different agents to circumvent the patent.
3. Patent Expiry and Freedom to Operate (FTO)
Given the 2004 filing date, the patent's term could extend to 20 years from the earliest priority date unless maintenance fees or legal issues impact validity. As of 2023, it might be nearing expiry, potentially opening opportunities for generic or alternative therapies.
Implications for Stakeholders
1. Pharmaceutical and Healthcare Industry
Owners of this patent can enforce exclusivity on the described treatment method, especially if it remained unchallenged. However, the scope’s breadth and prior art may limit enforceability to specific protocols.
2. Researchers & Innovators
Understanding the scope helps identify areas for innovation—e.g., novel compounds, alternative protocols, or combination therapies not covered by the patent.
3. Patent Strategy
Competitors should analyze the claims' specifics to design around them. Without infringing, they may explore different agents, dosages, or treatment approaches.
Conclusion
The RU2004122109 patent encapsulates a specific method for managing atrial fibrillation, with claims likely focused on particular therapeutic protocols involving pharmacological agents. Its legal scope, while offering exclusivity over the described methods, depends heavily on claim specificity and prior art considerations. The patent landscape in Russia indicates overlaps with international patent filings and broader cardiology treatment innovations, requiring careful FTO analysis for market entry or licensing.
Key Takeaways
- Scope clarity: The patent covers specific treatment methods for atrial fibrillation, emphasizing protocol parameters rather than compounds.
- Strategic relevance: Its enforceability depends on how narrowly or broadly claims are constructed and the existence of prior art.
- Patent lifecycle: As it matures, it may unlock opportunities for generic or alternative therapies in Russia.
- Innovation opportunities: Developing novel agents, treatments, or applications outside the patent claims can bypass restrictions.
- Legal landscape awareness: Comprehensive patent landscape analysis is essential to avoid infringement and identify licensing prospects.
FAQs
1. Can I develop a new atrial fibrillation treatment that avoids infringing on RU2004122109?
Yes. By designing protocols that differ significantly in agents, dosages, schedules, or treatment mechanisms, you can avoid infringement. It’s advisable to conduct a freedom to operate analysis focusing on claims scope.
2. Is RU2004122109 still enforceable today?
Potentially, if the patent remains valid and enforceable, especially if it predates expiration periods or maintenance lapses. Confirming current legal status via patent databases is recommended.
3. Does this patent protect the active pharmaceutical ingredients?
No. It primarily protects a treatment method, not specific compounds. Patent protection for APIs would require separate filings.
4. Are similar patents available in other jurisdictions?
Likely. Filing in Russia suggests possible filings in international jurisdictions or PCT applications. Cross-jurisdictional analysis is recommended for comprehensive landscape mapping.
5. What is the significance of this patent for Russian patent law?
It exemplifies Russia’s approach to medical method patents, emphasizing detailed protocols in patent claims, and underscores the importance of specificity in healthcare innovation protection.
References
[1] Russian Patent Office (Rospatent), Patent RU2004122109.
[2] World Intellectual Property Organization (WIPO), Patent Landscape Reports.
[3] International Patent Classification (IPC), A61P (specific to diseases or conditions therapy).
[4] Similar treatment protocols and prior art disclosures in cardiology literature pre-2004.
